|
1.
|
Young LS and Rickinson AB: Epstein-Barr
virus: 40 years on. Nat Rev Cancer. 4:757–768. 2004.PubMed/NCBI
|
|
2.
|
Kuppers R: B cells under influence:
transformation of B cells by Epstein-Barr virus. Nat Rev Immunol.
3:801–812. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Wilhelm S, Carter C, Lynch M, et al:
Discovery and development of sorafenib: a multikinase inhibitor for
treating cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Abou-Alfa GK, Schwartz L, Ricci S, et al:
Phase II study of sorafenib in patients with advanced
hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kane RC, Farrell AT, Saber H, et al:
Sorafenib for the treatment of advanced renal cell carcinoma. Clin
Cancer Res. 12:7271–7278. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Llovet JM and Bruix J: Molecular targeted
therapies in hepatocellular carcinoma. Hepatology. 48:1312–1327.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Yang SY, Cui CL, Chi ZH, et al: Phase II
clinical trial of sorafenib plus local chemotherapy in the
treatment of metastatic renal cell carcinoma with pleural effusion.
Zhonghua Yi Xue Za Zhi. 92:2998–3000. 2012.(In Chinese).
|
|
9.
|
Galanis E, Anderson SK, Lafky JM, et al:
Phase II study of bevacizumab in combination with sorafenib in
recurrent glioblastoma (N0776): a north central cancer treatment
group trial. Clin Cancer Res. 19:4816–4823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Cervello M, Bachvarov D, Lampiasi N, et
al: Novel combination of sorafenib and celecoxib provides
synergistic anti-proliferative and pro-apoptotic effects in human
liver cancer cells. PLoS One. 8:e655692013. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Wilhelm SM, Adnane L, Newell P, et al:
Preclinical overview of sorafenib, a multikinase inhibitor that
targets both Raf and VEGF and PDGF receptor tyrosine kinase
signaling. Mol Cancer Ther. 7:3129–3140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Huber S, Oelsner M, Decker T, et al:
Sorafenib induces cell death in chronic lymphocytic leukemia by
translational downregulation of Mcl-1. Leukemia. 25:838–847. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Lu X, Tang X, Guo W, et al: Sorafenib
induces growth inhibition and apoptosis of human chondrosarcoma
cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol.
102:821–826. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Liu LP, Ho RL, Chen GG and Lai PB:
Sorafenib inhibits hypoxia-inducible factor-1α synthesis:
implications for antiangiogenic activity in hepatocellular
carcinoma. Clin Cancer Res. 18:5662–5671. 2012.
|
|
15.
|
Reddy KB, Nabha SM and Atanaskova N: Role
of MAP kinase in tumor progression and invasion. Cancer Metastasis
Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Kim KN, Ham YM, Moon JY, et al: Acanthoic
acid induces cell apoptosis through activation of the p38 MAPK
pathway in HL-60 human promyelocytic leukaemia. Food Chem.
135:2112–2117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Han X, Xu B, Beevers CS, et al: Curcumin
inhibits protein phosphatases 2A and 5, leading to activation of
mitogen-activated protein kinases and death in tumor cells.
Carcinogenesis. 33:868–875. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Hyun MS, Hur JM, Mun YJ, et al: BBR
induces apoptosis in HepG2 cell through an
Akt-ASK1-ROS-p38MAPKs-linked cascade. J Cell Biochem. 109:329–338.
2010.PubMed/NCBI
|
|
19.
|
Rahmani M, Davis EM, Crabtree TR, et al:
The kinase inhibitor sorafenib induces cell death through a process
involving induction of endoplasmic reticulum stress. Mol Cell Biol.
27:5499–5513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Reed JC: Bcl-2 family proteins: regulators
of apoptosis and chemoresistance in hematologic malignancies. Semin
Hematol. 34:9–19. 1997.PubMed/NCBI
|
|
21.
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Chao DT and Korsmeyer SJ: BCL-2 family:
regulators of cell death. Annu Rev Immunol. 16:395–419. 1998.
View Article : Google Scholar
|
|
23.
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Fresno Vara JA, Casado E, de Castro J, et
al: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev.
30:193–204. 2004.PubMed/NCBI
|
|
25.
|
Chiu WH, Luo SJ, Chen CL, et al: Vinca
alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1
downregulation, DNA damage, mitochondrial dysfunction, and
apoptosis in lung adenocarcinoma cells. Biochem Pharmacol.
83:1159–1171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Matsuzawa A and Ichijo H:
Stress-responsive protein kinases in redox-regulated apoptosis
signaling. Antioxid Redox Signal. 7:472–481. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Budihardjo I, Oliver H, Lutter M, et al:
Biochemical pathways of caspase activation during apoptosis. Annu
Rev Cell Dev Biol. 15:269–290. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Green DR: At the gates of death. Cancer
Cell. 9:328–330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Wei MC, Zong WX, Cheng EH, et al:
Proapoptotic BAX and BAK: a requisite gateway to mitochondrial
dysfunction and death. Science. 292:727–730. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Wolter KG, Hsu YT, Smith CL, et al:
Movement of Bax from the cytosol to mitochondria during apoptosis.
J Cell Biol. 139:1281–1292. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Kuwana T, Mackey MR, Perkins G, et al:
Bid, Bax, and lipids cooperate to form supramolecular openings in
the outer mitochondrial membrane. Cell. 111:331–342. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Ghatan S, Larner S, Kinoshita Y, et al:
P38 MAP kinase mediates Bax translocation in nitric oxide-induced
apoptosis in neurons. J Cell Biol. 150:335–347. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Tsuruta F, Sunayama J, Mori Y, et al: JNK
promotes Bax translocation to mitochondria through phosphorylation
of 14-3-3 proteins. EMBO J. 23:1889–1899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Chai H, Luo AZ, Weerasinghe P, et al:
Sorafenib downregulates ERK/Akt and STAT3 survival pathways and
induces apoptosis in a human neuroblastoma cell line. Int J Clin
Exp Pathol. 3:408–415. 2010.PubMed/NCBI
|
|
35.
|
Oh SJ, Erb HH, Hobisch A, et al: Sorafenib
decreases proliferation and induces apoptosis of prostate cancer
cells by inhibition of the androgen receptor and Akt signaling
pathways. Endocr Relat Cancer. 19:305–319. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Sánchez-Hernández I, Baquero P, Calleros
L, et al: Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR
pathway cooperates to induce apoptosis in melanoma cells through a
MEK-independent mechanism. Cancer Lett. 314:244–255.
2012.PubMed/NCBI
|
|
37.
|
Ou DL, Shen YC, Yu SL, et al: Induction of
DNA damage-inducible gene GADD45beta contributes to
sorafenib-induced apoptosis in hepatocellular carcinoma cells.
Cancer Res. 70:9309–9318. 2010. View Article : Google Scholar : PubMed/NCBI
|
